Rick Winningham

Insider profile

Currently holds positions in Theravance Biopharma Inc, OncoMed Pharmaceuticals Inc and Jazz Pharmaceuticals PLC

Performance

Overall performance
3.5
Performance over holding periods
3.5
30 days 90 days 120 days
Average return 4% 8.2% 15.1%
Success rate 76% 68% 82%
Transactions
8 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chairman of the Board, Chief Executive Officer Theravance Biopharma Inc None -
Director OncoMed Pharmaceuticals Inc June 24, 2015 -
Independent Director Jazz Pharmaceuticals PLC May 1, 2010 -
Chairman of the Board Innoviva Inc Aug. 15, 2014 - Oct. 30, 2014
Chairman of the Board, Chief Executive Officer Innoviva Inc April 1, 2010 - Aug. 15, 2014
Rick Winningham's trades of Jazz Pharmaceuticals PLC's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
26.35
Quantity 64,900
Value US$4,283,764
Transaction date
Sale
Price
74.32
Quantity 7,848 +19.8%
Value US$1,283,022
Transaction date
Proposed sale
Price
99.02
Quantity 39,872
Value US$2,864,466
Transaction date
Sale
Price
180.86
Quantity 5,500 -38.2%
Value US$994,728
Transaction date
Proposed sale
Price
180.86
Quantity 5,500
Value US$994,728
Transaction date
Proposed sale
Price
112.00
Quantity 3,731
Value US$417,872
Transaction date
Proposed sale
Price
111.00
Quantity 3,075
Value US$341,325
Transaction date
Proposed sale
Price
135.18
Quantity 2,561
Value US$346,196
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-31 2026-08-31
PrS Proposed sale
64,900
26.35
US$4,283,764 		64,900 26.35 US$4,283,764
2026-05-27 2026-05-22
S Sale
7,848 +19.8%
74.32
US$1,283,022 		7,848 +19.8% 74.32 US$1,283,022
2026-05-22 2026-05-22
PrS Proposed sale
39,872
99.02
US$2,864,466 		39,872 99.02 US$2,864,466
2025-11-20 2025-11-18
S Sale
5,500 -38.2%
180.86
US$994,728 		5,500 -38.2% 180.86 US$994,728
2025-11-18 2025-11-18
PrS Proposed sale
5,500
180.86
US$994,728 		5,500 180.86 US$994,728
2025-08-08 2025-08-08
PrS Proposed sale
3,731
112.00
US$417,872 		3,731 112.00 US$417,872
2024-08-05 2024-08-06
PrS Proposed sale
3,075
111.00
US$341,325 		3,075 111.00 US$341,325
2023-08-15 2023-08-14
S Sale
1,241 -10.6%
138.16
US$171,455 		1,241 -10.6% 138.16 US$171,455
2023-08-14 2023-08-14
PrS Proposed sale
2,561
135.18
US$346,196 		2,561 135.18 US$346,196
2022-12-16 2022-12-14
S Sale
50,000 -3.6%
11.19
US$559,500 		50,000 -3.6% 11.19 US$559,500
2022-08-09 2022-08-08
S Sale
1,089 -11.2%
152.32
US$165,879 		1,089 -11.2% 152.32 US$165,879
2020-08-10 2020-08-07
S Sale
931 -13.1%
125.87
US$117,185 		931 -13.1% 125.87 US$117,185
2018-08-13 2018-08-10
S Sale
660 -11.8%
176.61
US$116,563 		660 -11.8% 176.61 US$116,563
2016-08-17 2016-08-15
S Sale
633 -4.0%
136.45
US$86,373 		633 -4.0% 136.45 US$86,373